Pharmaceutical

Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sabestomig?

Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma.

Apr 17, 2024 - 00:00
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-...

Next Article

With its squishy synthetic platelets, the startup SelSym seeks to reduce risk fr...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The Senate health committee looks into its first subpoena in 40 years

The Senate health committee looks into its first subpoe...

Jan 20, 2024

FDA approves Alvotech and Teva’s SELARSDI for new indications

FDA approves Alvotech and Teva’s SELARSDI for new indic...

Oct 24, 2024

STAT+: Researchers create talking throat patch for people with voice disorders

STAT+: Researchers create talking throat patch for peop...

Mar 13, 2024